Loading...
Please wait, while we are loading the content...
Similar Documents
Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers.
| Content Provider | Europe PMC |
|---|---|
| Author | Romero Prada, Martin Roa, Carolina Alfonso, Pamela Acero, German Huérfano, Lina Vivas-Consuelo, David |
| Copyright Year | 2018 |
| Abstract | ABSTRACT Introduction: Diabetic foot ulcers are one of the most frequent complications of diabetes; such ulcers cause an increase in the costs of the health care of the diabetic patient and can even cause disability due to amputation in the patient. Although a proportion of patients achieve a spontaneous closure of ulcers, others require medical or surgical treatment. Objective: To determine the cost-effectiveness of the intra- and perilesional application of recombinant human epidermal growth factor (rhEGF), as opposed to conventional therapy for the management of patients diagnosed with Wagner’s 3 or 4 diabetic foot ulcer in Colombia. Methodology: Using a Markov model, the process of care of a diabetic patient with diagnosis of Wagner’s 3 or 4 ulcer receiving conventional treatment, or intra- and perilesional rhEGF, is configured. The evaluation cycles of the treatments are weekly over a 5-year horizon and the outcomes evaluated are quality-adjusted life years (QALYs) and the number of amputations avoided by each treatment scheme, in addition to the total costs for treatments. Results: For the analysed base case, in the outcome of amputations, it was found that the factor presents 39 fewer amputations, in a cohort of 100 patients, compared with conventional treatment. Likewise, QALYs are 0.65 more with the use of rhEGF in an average patient. The estimated cost-utility ratio for the base case would be below the threshold established for Colombia. Conclusions: The intra- and perilesional application of rhEGF is a more effective therapeutic option than conventional therapy in the treatment of patients with Wagner’s 3 or 4 diabetic foot ulcers and is cost-effective, taking as an outcome the QALYs for Colombia from the perspective of the health system. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6022247&blobtype=pdf |
| Page Count | 8 |
| Volume Number | 9 |
| PubMed Central reference number | PMC6022247 |
| Issue Number | 1 |
| PubMed reference number | 29963295 |
| Journal | Diabetic Foot & Ankle [Diabet Foot Ankle] |
| e-ISSN | 2000625X |
| DOI | 10.1080/2000625x.2018.1480249 |
| Language | English |
| Publisher | Taylor & Francis |
| Publisher Date | 2018-06-26 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Subject Keyword | Epidermal growth factor diabetic foot diabetes mellitus wound healing amputation |
| Content Type | Text |
| Resource Type | Article |
| Subject | Podiatry Internal Medicine |
